Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment

Metabolism: Clinical and Experimental

Volumn 54, Issue 6, 2005, Pages 741-747

  Lahoz, Carlos ^a   Peña, Rocío ^a   Mostaza, Jose M ^a   Laguna, Fernando ^a   García Iglesias, María F ^a   Taboada, Manuel ^b   Pintó, Xavier ^c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Centro de Salud de Alcobendas   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE FACILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SAMPLE SIZE; SMOKING HABIT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; CHOLESTEROL, LDL; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PRAVASTATIN; PROSPECTIVE STUDIES; RECEPTORS, LDL;

EID: 19444380163     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.12.020     Document Type: Article

References (46)

1. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N. Engl. J. Med. 333 1995 1301 1307
2. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
4. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N. Engl. J. Med. 335 1996 1001 1009
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N. Engl. J. Med. 339 1998 1349 1357
6. T. Walley, P. Folino-Gallo, U. Schwabe, and E. van Ganse Variations and increase in use of statins across Europe: Data from administrative databases BMJ 328 2004 385 386
7. J. Davignon, and R. Laaksonen Low-density lipoprotein-independent effects of statins Curr. Opin. Lipidol. 10 1999 543 559
8. P. Jones, S. Kafonek, I. Laurora, and D. Hunninghake Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am. J. Cardiol. 81 1998 582 587
9. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation 97 1998 1440 1445
10. J. Pedro-Botet, E.J. Schaefer, and R.G. Bakker-Arkema Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner Atherosclerosis 158 2001 183 193
11. A.R. Miserez, F.A. Rossi, and U. Keller Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects Eur. J. Clin. Pharmacol. 46 1994 107 114
12. E. Leitersdorf Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia Drugs 47 Suppl. 2 1994 54 58
13. K. Nakajima Sex-related differences in response of plasma lipids to simvastatin: The Saitama Postmenopausal Lipid Intervention Study. S-POLIS Group Clin. Ther. 21 1999 2047 2057
14. C.L. Shear, F.A. Franklin, and S. Stinnett Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins Circulation 85 1992 1293 1303
15. L. Streja, C.J. Packard, J. Shepherd, S. Cobbe, and I. Ford Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS) Am. J. Cardiol. 90 2002 731 736
16. E. Leitersdorf, S. Eisenberg, and O. Eliav Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia Circulation 87 1993 35 44
17. K.A. Dornbrook-Lavender, and J.A. Pieper Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy Cardiovasc. Drugs Ther. 17 2003 75 82
18. C. Lahoz, R. Pena, and J.M. Mostaza Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy Atherosclerosis 168 2003 289 295
19. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II) JAMA 269 1993 3015 3023
20. D.B. Hunninghake, R.H. Knopp, and G. Schonfeld Efficacy and safety of pravastatin in patients with primary hypercholesterolemia: I. A dose-response study Atherosclerosis 85 1990 81 89
21. R. McPherson, J. Bedard, and P. Connelly Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia Clin. Ther. 14 1992 276 291
22. L.J. Lambrecht, and P.L. Malini Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group Acta Cardiol. 48 1993 541 554
23. H.G. Fieseler, V.W. Armstrong, and E. Wieland Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor pravastatin: Results of a 2-year investigation Clin. Chim. Acta 204 1991 291 300
24. D.B. Hunninghake, E.A. Stein, and M.J. Mellies Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a J. Clin. Pharmacol. 33 1993 574 780
25. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group Am. J. Cardiol. 71 1993 1408 1414
26. J.M. McKenney, L.S. McCormick, S. Weiss, M. Koren, S. Kafonek, and D.M. Black A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group Am. J. Med. 104 1998 137 143
27. S. Gonbert, S. Malinsky, and A.C. Sposito Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk Atherosclerosis 164 2002 305 311
28. I.C. Klausen, L.U. Gerdes, H. Meinertz, F.A. Hansen, and O. Faergeman Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration Eur. J. Clin. Invest. 23 1993 240 245
29. Y. Narita, Y. Kitazoe, and Y. Kurihara Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels Eur. J. Clin. Pharmacol. 52 1997 461 463
30. S. Drmanac, D.C. Heilbron, and C.R. Pullinger Elevated baseline triglyceride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins J. Cardiovasc. Pharmacol. Ther. 6 2001 47 56
31. C.J. Packard, and J. Shepherd Lipoprotein heterogeneity and apolipoprotein B metabolism Arterioscler. Thromb. Vasc. Biol. 17 1997 3542 3556
32. A.M. Scanu, R.M. Lawn, and K. Berg Lipoprotein(a) and atherosclerosis Ann. Intern. Med. 115 1991 209 218
33. Scanu AM. Lipoprotein(a), Friedewald formula, and NCEP guidelines. National Cholesterol Education Program. Am J Cardiol 2001;87:608-609, A9.
34. R. Pena, C. Lahoz, and J.M. Mostaza Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting J. Intern. Med. 251 2002 518 525
35. J.P. Ojala, E. Helve, C. Ehnholm, K. Aalto-Setala, K.K. Kontula, and M.J. Tikkanen Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia J. Intern. Med. 230 1991 397 405
36. C. Sanllehy, E. Casals, and C. Rodriguez-Villar Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia Metabolism 47 1998 560 565
37. L.U. Gerdes, C. Gerdes, and K. Kervinen The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study Circulation 101 2000 1366 1371
38. J.M. Ordovas, J. Lopez-Miranda, and F. Perez-Jimenez Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy Atherosclerosis 113 1995 157 166
39. P. de Knijff, and L.M. Havekes Apolipoprotein E as a risk factor for coronary heart disease: A genetic and molecular biology approach Curr. Opin. Lipidol. 7 1996 59 63
40. D. Corella, M. Guillen, and C. Saiz Environmental factors modulate the effect of the APOE genetic polymorphism on plasma lipid concentrations: Ecogenetic studies in a Mediterranean Spanish population Metabolism 50 2001 936 944
41. L.A. Salazar, M.H. Hirata, and S.D. Giannini Effects of AvaII and HincII polymorphisms at the LDL receptor gene on serum lipid levels of Brazilian individuals with high risk for coronary heart disease J. Clin. Lab. Anal. 13 1999 251 258
42. Y.I. Ahn, M.I. Kamboh, C.E. Aston, R.E. Ferrell, and R.F. Hamman Role of common genetic polymorphisms in the LDL receptor gene in affecting plasma cholesterol levels in the general population Arterioscler. Thromb. 14 1994 663 670
43. L.A. Salazar, M.H. Hirata, and N. Forti PvuII intron 15 polymorphism at the LDL receptor gene is associated with differences in serum lipid concentrations in subjects with low and high risk for coronary artery disease from Brazil Clin. Chim. Acta 293 2000 75 88
44. L.A. Salazar, M.H. Hirata, E.C. Quintao, and R.D. Hirata Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia J. Clin. Lab. Anal. 14 2000 125 131
45. L.A. Salazar, M.H. Hirata, and S.D. Giannini Seven DNA polymorphisms at the candidate genes of atherosclerosis in Brazilian women with angiographically documented coronary artery disease Clin. Chim. Acta 300 2000 139 149
46. A.H. Maitl-van der Zee, O.H. Klungel, and B.H. Stricker Genetic polymorphisms: Importance for response to HMG-CoA reductase inhibitors Atherosclerosis 163 2002 213 222